Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 11Fallopian Tube Neoplasms 9Neuroblastoma 6Neoplasm Metastasis 3Lung Neoplasms 3Ganglioneuroblastoma 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Rhabdoid Tumor 2Recurrence 2Leukemia, Myeloid, Acute 2Glioma 2Central Nervous System Neoplasms 2Wilms Tumor 1Thrombocythemia, Essential 1SCLC 1Primary Myelofibrosis 1Polycythemia Vera 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3Cyclophosphamide 3pembrolizumab 2oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1denileukin diftitox 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Palliative Care 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Topotecan × 90 days × Clear all
NCT05613088 2026-04-30

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Bristol-Myers Squibb

Phase 2 Completed
106 enrolled 23 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
404 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
384 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡